Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-19T11:48:21.647Z Has data issue: false hasContentIssue false
  • English
  • Français

Distigmine bromide induced acute psychotic disorder in a patient with multiple sclerosis

Published online by Cambridge University Press:  16 April 2020

Hubertus Himmerich ,
Armin Szegedi ,
Christoph Klawe ,
Ion Anghelescu  and
Matthias J. Müller
Hubertus Himmerich*
Affiliation:
Max Planck Institute of Psychiatry, Kraepelinstraße 2–10, 80804Munich, Germany
Armin Szegedi
Affiliation:
Department of Psychiatry, University of Mainz, Untere Zahlbacher Straße 8, 55131Mainz, Germany
Christoph Klawe
Affiliation:
Department of Psychiatry, University of Mainz, Untere Zahlbacher Straße 8, 55131Mainz, Germany
Ion Anghelescu
Affiliation:
Department of Psychiatry, University Hospital Benjamin Franklin, Free University of Berlin, Eschenallee 3, 14050Berlin, Germany
Matthias J. Müller
Affiliation:
Department of Psychiatry, University of Mainz, Untere Zahlbacher Straße 8, 55131Mainz, Germany
*
*Corresponding author. E-mail address: himmerich@mpipsykl.mpg.de (H. Himmerich).
Get access

Abstract

A female patient with multiple sclerosis (MS) suffered from an acute psychotic disorder after taking distigmine bromide for detrusor dysfunction. She showed a dramatic relief of her symptoms after the medication, distigmine bromide, was stopped. Distigmine is not supposed to penetrate the blood-brain barrier (BBB). However, in MS patients a leakage of the BBB could be hypothesized.

Keywords

Distigmine bromideMultiple sclerosisBlood-brain barrier
Type
Case report
Information
European Psychiatry , Volume 18 , Issue 6 , October 2003 , pp. 318 - 319
Copyright
Copyright © Éditions scientifiques et médicales Elsevier SAS 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Claudio, L, Brosnan, CF. Effects of prazosin on the blood–brain barrier during experimental autoimmune encephalomyelitis. Brain Res 1992;594(2):233-43.CrossRefGoogle ScholarPubMed
Chaudhuri, JD. Blood–brain barrier and infection. Med Sci Monit 2000;6(6):1213-22.Google ScholarPubMed
Kusuhara, H, Sugiyama, Y. Efflux transport systems for drugs at the blood–brain barrier and blood–cerebrospinal fluid barrier (Part 2). Drug Discov Today 2001;6(4):206-12.CrossRefGoogle Scholar
Ogura, H, Kosasa, T, Kuriya, Y, Yamanishi, Y. Central and peripheral activity of cholinesterase inhibitors as revealed by yawning and fasciculation in rats. Eur J Pharmacol 2001;415(2–3):157-64.CrossRefGoogle ScholarPubMed
Melchior, H. Drug therapy of detrusor dysfunction. Urologe 1983;22(3):167-75.Google ScholarPubMed
Hertrich, O. Psychopharmacologically qualified side effects with distigmine bromide therapy (UBRETID, BC 51). Nervenarzt 1976;46:264-7.Google Scholar
Handler, CE. Convulsions after distigmine bromide. Anaesth Intensive Care 1982;10(2):168-9.Google ScholarPubMed
Kay, SR, Fiszbein, A, Opler, LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.CrossRefGoogle Scholar
Karch, FE, Lasagna, L. Adverse drug reactions. A critical review. J Am Med Assoc 1975;234(12):1236-41.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.